3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Prostatic Neoplasms
7
Pancreatic Neoplasms
4
Urinary Bladder Neoplasms
3
Ovarian Neoplasms
3
Hematologic Neoplasms
3
Breast Neoplasms
3
Neoplasms
2
Multiple Myeloma
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Thyroid Neoplasms
1
Thrombocytosis
1
Stomach Neoplasms
1
Skin Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Interventions
Nivolumab
5
pembrolizumab
4
Ipilimumab
2
Drug Therapy
2
Biopsy
2
poly ICLC
1
pertuzumab
1
osimertinib
1
montanide ISA 51
1
liposomal doxorubicin
1
flt3 ligand protein
1
cobimetinib
1
cemiplimab
1
cc-486
1
brodalumab
1
Trastuzumab
1
Tissue Banks
1
Surveys and Questionnaires
1
Standard of Care
1
Specimen Handling
1
Radiotherapy
1
Radiosurgery
1
Quality of Life
1
Psychiatric Rehabilitation
1
Poly I-C
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Oxaliplatin
1
Observation
1
Molecular Diagnostic Techniques
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Skin Neoplasms
×
pertuzumab
×
Genitourinary
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled